MX2011007061A - Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica. - Google Patents

Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica.

Info

Publication number
MX2011007061A
MX2011007061A MX2011007061A MX2011007061A MX2011007061A MX 2011007061 A MX2011007061 A MX 2011007061A MX 2011007061 A MX2011007061 A MX 2011007061A MX 2011007061 A MX2011007061 A MX 2011007061A MX 2011007061 A MX2011007061 A MX 2011007061A
Authority
MX
Mexico
Prior art keywords
group
alkyl
nr5r6
aryl
groups
Prior art date
Application number
MX2011007061A
Other languages
English (en)
Inventor
Jean-Michel Altenburger
Valerie Fossey
Stephane Illiano
Geraldine Manette
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0807475A external-priority patent/FR2940652B1/fr
Priority claimed from FR0904091A external-priority patent/FR2949468B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2011007061A publication Critical patent/MX2011007061A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La inversión se refiere a los compuestos que responden a la formula (I), en estado de base o de sal por adicción de un acido: (I) en la cual n es igual a 0, 1, 2, 3 o 4; m es igual a 0, 1 o 2; o es igual a 0 o 1; X representa un grupo -CH2, -CH(R`)-,- NH(R`)- o un heteroátomo seleccionado entre O y S, entendiéndose que R` representa un grupo alquilo (C1_C5)alquilo, alcoxi (C1-C5), -CH2-arilo, -C(O)R5 o COOR5; R1 representa un grupo seleccionado entre los grupos (i) alquilo (C1-C5),(ii) alcoxi (C1-C5), (iii)- COOR5,(iv)- NR5R6, (v) -C(O)-NR5R6, (vi) -SO2 -NR3R4, (vii) heteroarilo eventualmente sustituido con un grupo alquilo (C1-C5), (viii)-W-arilo, (xi)-W-heteroarilo, (x) -O-W-arilo, (xi) -O-W-heteroarilo y (xii) -O-W- NR5R6; entendiendo que R3 y R4, (i) que pueden ser idénticos o diferentes, representa independientemente uno de otro, un átomo H, un grupo alqilo (C1-C5), cicloalquilo (C3-C6), arilo, heteroarilo, -CH2 -heteroarilo, alquil (C1-C5)-NR5R6,-W-OH o -W-NR5R6; o (ii) forman junto con el átomo de nitrógeno que los porta un grupo heterocicloalquilo eventualmente sustituido con uno o varios grupos seleccionados entre los grupos alquilo (C1-C5) y -CH2-arilo; w es un grupo alquileno-(C1-C5), eventualmente sustituido con uno o varios grupos hoidroxi; R5 y R6, que pueden ser idénticos o diferentes, representan, independendientemente uno de otro, un átomo de hidrogeno o un grupo seleccionado entre los grupos alquilo (C1-C5) y los grupos cicloalquilo (C3-C6), así como su procedimiento de preparación y sus aplicaciones en terapéutica.
MX2011007061A 2008-12-29 2009-12-24 Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica. MX2011007061A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0807475A FR2940652B1 (fr) 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
FR0904091A FR2949468B1 (fr) 2009-08-28 2009-08-28 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
PCT/FR2009/052692 WO2010076525A1 (fr) 2008-12-29 2009-12-24 Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
MX2011007061A true MX2011007061A (es) 2011-12-16

Family

ID=41728182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007061A MX2011007061A (es) 2008-12-29 2009-12-24 Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica.

Country Status (34)

Country Link
US (2) US8697731B2 (es)
EP (1) EP2382215B1 (es)
JP (1) JP5865704B2 (es)
KR (1) KR101630475B1 (es)
CN (1) CN102333776B (es)
AR (1) AR074916A1 (es)
AU (1) AU2009334570B2 (es)
BR (1) BRPI0923875A2 (es)
CA (1) CA2748413A1 (es)
CO (1) CO6400145A2 (es)
CR (1) CR20110360A (es)
CY (1) CY1115635T1 (es)
DK (1) DK2382215T3 (es)
EA (1) EA019774B1 (es)
EC (1) ECSP11011164A (es)
ES (1) ES2511917T3 (es)
HK (1) HK1163679A1 (es)
IL (1) IL213790A (es)
MA (1) MA32978B1 (es)
MX (1) MX2011007061A (es)
MY (1) MY155244A (es)
NI (1) NI201100132A (es)
NZ (1) NZ593797A (es)
PA (1) PA8856101A1 (es)
PE (1) PE20120338A1 (es)
PL (1) PL2382215T3 (es)
PT (1) PT2382215E (es)
SG (1) SG172422A1 (es)
SI (1) SI2382215T1 (es)
SM (1) SMT201400157B (es)
TN (1) TN2011000308A1 (es)
TW (1) TWI441828B (es)
WO (1) WO2010076525A1 (es)
ZA (1) ZA201104785B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2382215T3 (pl) 2008-12-29 2015-01-30 Sanofi Sa Pochodne 2-pirydyny-2-ylo-pirazol-3(2H)-onu, ich wytwarzanie i zastosowanie terapeutyczne
EP2361912A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2832733B1 (en) 2012-03-30 2018-08-29 Daiichi Sankyo Company, Limited 4-alkanoylamino-3-pyrazolone derivative
CN102731384B (zh) * 2012-07-10 2016-04-06 南开大学 一种6-甲基烟酸叔丁酯的合成方法
CN105492433B (zh) 2013-03-29 2018-11-23 武田药品工业株式会社 6-(5-羟基-1h-吡唑-1-基)烟碱酰胺衍生物和其作为phd抑制剂的用途
CN105061316B (zh) * 2015-07-17 2017-12-22 苏州大学 稠环类化合物、制备方法和用途
CN113072562B (zh) * 2021-04-06 2022-01-14 山东大学 一种GSK-3β抑制剂及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3917469A1 (de) * 1989-05-30 1990-12-06 Bayer Ag Heterocyclylpyridine
DE4023488A1 (de) 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
CA2530679A1 (en) * 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
KR20090066297A (ko) * 2006-10-16 2009-06-23 화이자 프로덕츠 인크. 치료용 피라졸릴 티에노피리딘
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
WO2008141731A2 (en) * 2007-05-18 2008-11-27 Bayer Healthcare Ag Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PL2382215T3 (pl) 2008-12-29 2015-01-30 Sanofi Sa Pochodne 2-pirydyny-2-ylo-pirazol-3(2H)-onu, ich wytwarzanie i zastosowanie terapeutyczne
MY179093A (en) 2008-12-29 2020-10-27 Sanofi Sa Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators

Also Published As

Publication number Publication date
US9359329B2 (en) 2016-06-07
TWI441828B (zh) 2014-06-21
KR20110111437A (ko) 2011-10-11
US20160137627A9 (en) 2016-05-19
JP5865704B2 (ja) 2016-02-17
US20110301148A1 (en) 2011-12-08
TN2011000308A1 (fr) 2012-12-17
ZA201104785B (en) 2012-09-26
AU2009334570A1 (en) 2011-07-21
CY1115635T1 (el) 2017-01-04
JP2012513977A (ja) 2012-06-21
MA32978B1 (fr) 2012-01-02
DK2382215T3 (da) 2014-10-27
PE20120338A1 (es) 2012-04-30
PA8856101A1 (es) 2010-07-27
PT2382215E (pt) 2014-10-16
IL213790A0 (en) 2011-07-31
ECSP11011164A (es) 2011-07-29
PL2382215T3 (pl) 2015-01-30
NI201100132A (es) 2011-11-01
TW201028424A (en) 2010-08-01
WO2010076525A1 (fr) 2010-07-08
HK1163679A1 (en) 2012-09-14
EP2382215A1 (fr) 2011-11-02
EA019774B1 (ru) 2014-06-30
SI2382215T1 (sl) 2020-06-30
AU2009334570B2 (en) 2016-06-09
ES2511917T3 (es) 2014-10-23
AR074916A1 (es) 2011-02-23
IL213790A (en) 2015-09-24
SMT201400157B (it) 2015-01-15
EA201170900A1 (ru) 2012-02-28
NZ593797A (en) 2013-01-25
US8697731B2 (en) 2014-04-15
KR101630475B1 (ko) 2016-06-14
CN102333776A (zh) 2012-01-25
BRPI0923875A2 (pt) 2015-07-21
CA2748413A1 (fr) 2010-07-08
MY155244A (en) 2015-09-30
CO6400145A2 (es) 2012-03-15
CR20110360A (es) 2011-10-13
CN102333776B (zh) 2014-05-21
SG172422A1 (en) 2011-07-28
US20140194470A1 (en) 2014-07-10
EP2382215B1 (fr) 2014-07-16

Similar Documents

Publication Publication Date Title
MX2011007061A (es) Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica.
MX2010013275A (es) Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano.
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
MY142807A (en) Benzimidazole derivative and use thereof.
MX2010003445A (es) Derivados de nicotinamida, su preparacion y su uso terapeutico.
TW200745034A (en) New compounds
MXPA06010097A (es) Inhibidores de dipeptidil peptidasa-iv.
EA200601847A1 (ru) Замещённые метиларил- или гетероариламидные соединения
UA101482C2 (ru) Способ получения 2'-дезокси-5-азацитидина (децитабина)
DE60301345D1 (de) Stabilisierte askorbinsäurederivate
NO20073787L (no) Nye pyrimidin-nukleosidforbindelser eller dets salt
EA014959B3 (ru) Ингибиторы глицинового переносчика-1
MX2007007446A (es) Procesos para la produccion de 4-aminoquinazolinas.
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
MY161992A (en) Novel tetrahydroisoquinoline derivative
ATE489367T1 (de) Verfahren und zwischenprodukt zur herstellung von donezepil
TW200619201A (en) Process for the preparation of pyrazoles
TW200738681A (en) Isoquinoline and benzo[h]isoquinoline derivatives, their preparation and their use in therapeutics
PL1819704T3 (pl) Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej
TNSN06337A1 (en) 6-substituted pyridoindolone derivatives production and therapeutic use thereof
TW200716112A (en) Benzimidazole compound
RS20060157A (en) Method for the manufacture of thip
ATE471333T1 (de) Neue zuckerderivate, verfahren für ihre zubereitung und ihre verwendung als oberflächenaktive mittel
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
DE602004020050D1 (de) Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte

Legal Events

Date Code Title Description
FG Grant or registration